1. Li T, Chiang JY. Nuclear receptors in bile acid metabolism. Drug Metab Rev. 2013; 45: 145-155.
2. Alnouti Y. Bile Acid sulfation: a pathway of bile acid elimination and detoxification.Toxicol Sci. 2009; 108: 225-246.
3. Trottier J, Milkiewicz P, Kaeding J, Verreault M, Barbier O. Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors. Mol Pharm. 2006; 3: 212-222.
4. Botham KM, Boyd GS. The metabolism of chenodeoxycholic acid to beta- muricholic acid in rat liver. Eur J Biochem. 1983; 134: 191-196.
5. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy.Pharmacol Rev. 2014; 66: 948-983.
6. Wang TY, Liu M, Portincasa P, Wang DQ. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Invest. 2013; 43: 1203- 1223.
7. Fine KD, Fordtran JS. The effect of diarrhea on fecal fat excretion.Gastroenterology. 1992; 102: 1936-1939.
8. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a Nuclear Receptor for Bile Acids. Science. 1999; 284: 1362.
9. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999; 284: 1365-1368.
10. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010; 8: e005.
11. Piglionica M, Cariello M, Moschetta A. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19. Curr Opin Pharmacol. 2018; 43: 93-98.
12. Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015; 125: 386-402.
13. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000; 6: 517- 526.
14. Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000; 6: 507-515.
15. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000; 102: 731-744.
16. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem. 2001; 276: 28857-28865.
17. Lambert G, Amar MJ, Guo G, Brewer HB, Jr., Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem. 2003; 278: 2563-2570.
18. Miyake JH, Doung XD, Strauss W, et al. Increased production of apolipoprotein B- containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7alpha-hydroxylase. J Biol Chem. 2001; 276: 23304-23311.
19. Liu Y, Song A, Yang X, et al. Farnesoid X receptor agonist decreases lipid accumulation by promoting hepatic fatty acid oxidation in db/db mice. Int J Mol Med. 2018; 42: 1723-1731.
20. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003; 17: 259-272.
21. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids. 2014;86: 62-68.
22. Kliewer SA, Mangelsdorf DJ. Bile Acids as Hormones: The FXR-FGF15/19 Pathway. Dig Dis. 2015; 33: 327-331.
23. Watanabe S, Fujita K, Tsuneyama K, Nose M. Changes in liver lipidomics associated with sodium cholate-induced liver injury and its prevention by boiogito, a Japanese herbal medicine, in mice. Traditional & Kampo Medicine. 2016; 3: 9- 19.
24. Qian W, Hasegawa J, Cai X, et al. Components of Boiogito Suppress the Progression of Hypercholesterolemia and Fatty Liver Induced by High-Cholesterol Diet in Rats. Yonago Acta Med. 2016; 59: 67-80.
25. Qian W, Hasegawa J, Tsuno S, Endo Y, Matsuda A, Miura N. Effects of kampo formulas on the progression of hypercholesterolemia and Fatty liver induced by high-cholesterol diet in rats. Yonago Acta Med. 2014; 57: 147-158.
26. Zollner G, Trauner M. Mechanisms of cholestasis. Clin Liver Dis. 2008; 12: 1-26, vii.
27. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011; 178: 175-186.
28. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998; 339: 1217-1227.
29. Hofmann AF. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev. 2004; 36: 703-722.
30. Beilke LD, Besselsen DG, Cheng Q, Kulkarni S, Slitt AL, Cherrington NJ. Minimal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis. Toxicol Sci. 2008; 102: 196-204.
31. Wang YG, Zhou JM, Ma ZC, et al. Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin: a possible mechanism for its hepatoprotective property against lithocholic acid-induced injury. Chem Biol Interact. 2012; 200: 11- 20.
32. Zeng H, Li D, Qin X, et al. Hepatoprotective Effects of Schisandra sphenanthera Extract against Lithocholic Acid-Induced Cholestasis in Male Mice Are Associated with Activation of the Pregnane X Receptor Pathway and Promotion of Liver Regeneration. Drug Metab Dispos. 2016; 44: 337-342.
33. Miyata M, Nomoto M, Sotodate F, et al. Possible protective role of pregnenolone- 16 alpha-carbonitrile in lithocholic acid-induced hepatotoxicity through enhanced hepatic lipogenesis. Eur J Pharmacol. 2010; 636: 145-154.
34. Nomoto M, Miyata M, Shimada M, et al. ME3738 protects against lithocholic acid- induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Eur J Pharmacol. 2007; 574: 192-200.
35. Fujita K, Iguchi Y, Une M, Watanabe S. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist. Lipids. 2017; 52: 335-344.
36. Fickert P, Fuchsbichler A, Marschall HU, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol. 2006; 168: 410-422.
37. Owen BM, Milona A, van Mil S, et al. Intestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid. Drug Metab Dispos. 2010; 38: 143-149.
38. Cheng J, Fang ZZ, Kim JH, et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J Lipid Res. 2014; 55: 455-465.
39. Al-Dury S, Marschall HU. Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. Front Pharmacol. 2018; 9: 931.
40. Aldini R, Roda A, Lenzi PL, et al. Bile acid active and passive ileal transport in the rabbit: effect of luminal stirring. Eur J Clin Invest. 1992; 22: 744-750.
41. Chiang JY, Pathak P, Liu H, Donepudi A, Ferrell J, Boehme S. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. Dig Dis. 2017; 35: 241-245.
42. Burrin D, Stoll B, Moore D. Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways. J Anim Sci. 2013; 91: 1991-2000.
43. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015; 21: 159-165.
44. Moris D, Giaginis C, Tsourouflis G, Theocharis S. Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis. Curr Med Chem. 2017; 24: 1147-1157.
45. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004; 113: 1408-1418.
46. Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015; 6: 10166.
47. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989; 30: 719-730.
48. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37: 911-917.
49. Watanabe S, Tsuneyama K. Cattle bile but not bear bile or pig bile induces lipid profile changes and fatty liver injury in mice: mediation by cholic acid. J Toxicol Sci. 2012; 37: 105-121.
50. Eyssen H, De Pauw G, Stragier J, Verhulst A. Cooperative formation of omega- muricholic acid by intestinal microorganisms. Appl Environ Microbiol. 1983; 45: 141-147.
51. Wang DQ, Tazuma S. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res. 2002; 43: 1960- 1968.
52. Miyazaki M, Kim YC, Ntambi JM. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res. 2001; 42: 1018- 1024.
53. Attie AD, Krauss RM, Gray-Keller MP, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res. 2002; 43: 1899-1907.
54. Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res. 1982; 23: 70-80.
55. Altmann SW, Davis HR, Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303: 1201-1204.
56. Berr F, Kullak-Ublick GA, Paumgartner G, Münzing W, Hylemon PB. 7 alpha- dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology. 1996; 111: 1611-1620.
57. Vital M, Rud T, Rath S, Pieper DH, Schlüter D. Diversity of Bacteria Exhibiting Bile Acid-inducible 7α-dehydroxylation Genes in the Human Gut. Comput Struct Biotechnol J. 2019; 17: 1016-1019.
58. Eyssen HJ, De Pauw G, Van Eldere J. Formation of hyodeoxycholic acid from muricholic acid and hyocholic acid by an unidentified gram-positive rod termed HDCA-1 isolated from rat intestinal microflora. Appl Environ Microbiol. 1999; 65: 3158-3163.
59. Xi Y, Li H. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Biomed Pharmacother. 2020; 121: 109609.
60. Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17: 225-235.
61. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997; 21 Suppl 3: S12-23.
62. Jang HR, Park HJ, Kang D, et al. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Exp Mol Med. 2019; 51: 1-14.
63. Shimada T, Akase T, Kosugi M, Aburada M. Preventive Effect of Boiogito on Metabolic Disorders in the TSOD Mouse, a Model of Spontaneous Obese Type II Diabetes Mellitus. Evid Based Complement Alternat Med. 2011; 2011: 931073.